Literature DB >> 21206445

West syndrome, can topiramate be on top?

Raidah S Al-Baradie1, Maha A Elseed.   

Abstract

OBJECTIVE: To determine Topiramate efficacy on treatment of infantile spasms and ancillary seizures, and whether there were any improvements on EEG.
METHODS: A retrospective study of 18 patients with infantile spasms recruited from the Pediatric Unit at King Fahd Hospital of the University, Dammam University, Saudi Arabia was carried out between January 2004 and December 2008. Topiramate was used as treatment in 7 males and 11 females aged 2-14 months. The maximum dose was 12 mg/kg/day.
RESULTS: The etiology in 9 (50%) patients was cryptogenic, 6 (33%) symptomatic, and 3 (17%) idiopathic. After Topiramate treatment 6 (33%) were spasm free, 8 (44%) had ≥50% reduction, 2 (11%) had no change, and one (6%) had worsening of their spasms. Eight patients had ancillary seizures, 2 (25%) were seizure free, 2 (25%) had ≥50% seizure reduction, and 4 (50%) had no change in the ancillary seizure. The EEG showed hypsarrhythmia in 14 (78%). Post Topiramate, the EEG was normal in one (5%), improved in 3 (17%), showed persistent hypsarrhythmia in 8 (44%), and evolved to other features in 3 (17%). Three patients developed side effects such as weight loss and irritability, for which 2 patients stopped the medication.
CONCLUSION: Topiramate has a good effect on the clinical features of West syndrome, but not on the EEG. It was tolerated with minimal side effects.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21206445

Source DB:  PubMed          Journal:  Neurosciences (Riyadh)        ISSN: 1319-6138            Impact factor:   0.906


  2 in total

1.  Topiramate as an Adjunct in the Management of West Syndrome.

Authors:  Pallavi L Nadig; Jitendra Kumar Sahu; Renu Suthar; Arushi Saini; Naveen Sankhyan
Journal:  Indian J Pediatr       Date:  2019-11-13       Impact factor: 1.967

2.  Contributing factors to VEP grating acuity deficit and inter-ocular acuity difference in children with cerebral visual impairment.

Authors:  Nívea Nunes Cavascan; Solange Rios Salomão; Paula Yuri Sacai; Josenilson Martins Pereira; Daniel Martins Rocha; Adriana Berezovsky
Journal:  Doc Ophthalmol       Date:  2013-12-18       Impact factor: 2.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.